Form 4: Enliven Therapeutics CEO Samuel Kintz Sells Shares Under 10b5-1 Trading Plan

Enliven Therapeutics CEO Samuel Kintz sold 5,000 shares of common stock at an average price of $16.4906, executed under a pre-arranged 10b5-1 trading plan.

Summary

• On May 19, 2025, Samuel Kintz, the President and CEO of Enliven Therapeutics, sold 5,000 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 15, 2024.
• The shares were sold at a weighted average price of $16.4906, with individual trades ranging from $16.11 to $16.90.
• Following the transaction, Kintz directly owns no shares but indirectly owns 972,892 shares through The Kintz & Egan Trust Dated March 30, 2019, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-existing trading plan. It doesn't indicate any particular positive or negative outlook for the company.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It's common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The impact on the stock price is usually minimal unless the sale is unusually large.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, but is unlikely to have a significant impact due to the pre-planned nature of the sale.

Key Dates

Keywords

Form 4, Enliven Therapeutics, Samuel Kintz, Stock Sale, 10b5-1 Trading Plan, ELVN, Insider Trading